Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2018-04-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于硫酸氢氯吡格雷片（25mg）通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of a drug (Hydrogen Chloride Clopidogrel Sulfate Tablets 25mg) passing a consistency evaluation by the National Medical Products Administration. It includes details about the drug, approval, and market outlook. The document is short (618 characters) and is an announcement of regulatory approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types. This fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2018-04-11 Chinese
关于参股四川锦江电子科技有限公司暨增资的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the progress of its equity participation and capital increase in Sichuan Jinjiang Electronic Technology Co., Ltd. It details the completion of the equity transfer and capital increase, including changes in business registration information. The document is short (972 characters) and serves as a progress update on a financing and equity investment activity. It does not contain financial statements, audit information, or detailed financial results. It is not a full report but an announcement related to capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-04-10 Chinese
2017年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2017 年年度报告全文" which translates to "2017 Annual Report Full Text" for Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, and audited financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes comprehensive financial figures, business overview, risk factors, and management commentary, all consistent with an official annual report filing. Therefore, the document is classified as an Annual Report (10-K equivalent). FY 2017
2018-03-26 Chinese
第四届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of the 2017 annual supervisory board work report, the 2017 annual report and its summary, the 2017 profit distribution plan, internal control self-evaluation report, accounting policy changes, and other related matters. It explicitly states that the 2017 annual report and related documents are available on external disclosure media and will be submitted to the 2017 annual general meeting for approval. The document itself does not contain the full annual report or detailed financial statements but rather the resolutions and approvals related to these reports. The document length is 3377 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is an announcement of supervisory board meeting resolutions and approvals related to the annual report and other matters, not the annual report itself. This fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement of meeting resolutions and approvals without the full report content.
2018-03-26 Chinese
关于公司控股股东及其他关联方资金占用情况汇总表的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (Special Audit Report) concerning the summary table of funds occupied by controlling shareholders and other related parties for Shenzhen Salubris Pharmaceuticals Co., Ltd. It references the 2017 fiscal year and includes an audit opinion by a registered accounting firm. The content focuses on a specific audit of related-party fund occupation, not a full annual report or general audit report. The document length is 3316 characters, which is relatively short and focused. It is not a general annual report (10-K), nor a management report or earnings release. It is a standalone audit report on a specific issue related to related-party transactions, consistent with the definition of Audit Report / Information (AR). FY 2017
2018-03-26 Chinese
关于召开2017年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2017 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes information about the meeting date, location, voting procedures (both in-person and online), agenda items to be discussed and voted on, such as the 2017 annual report, board and supervisory reports, profit distribution plan, and appointment of auditors. It also contains procedural details like shareholder registration, proxy forms, and voting instructions. The document does not contain the actual annual report or financial statements but rather serves as a formal notification and invitation to shareholders to attend and vote at the AGM. Therefore, it fits the definition of AGM Information (AGM-R).
2018-03-26 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.